Bausch files patent suit against Norwich over generic Xifaxan

seekingalpha06-21

Bausch Health (NYSE:BHC) said it has filed a patent infringement suit against Norwich Pharmaceuticals in response to Norwich's filing of an application with the FDA to put out a generic version of ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2445727648?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/687472050/image_687472050.jpg","is_english":true,"pubTime":"2024-06-21 06:11","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2445727648","market":"sh","top_or_hot":-1,"title":"Bausch files patent suit against Norwich over generic Xifaxan","media":"seekingalpha","content":"<div>\n<p>Bausch Health (NYSE:BHC) said it has filed a patent infringement suit against Norwich Pharmaceuticals in response to Norwich's filing of an application with the FDA to put out a generic version of ...</p>\n\n<a href=\"https://seekingalpha.com/news/4117798-bausch-files-patent-suit-against-norwich-over-generic-xifaxan\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bausch files patent suit against Norwich over generic Xifaxan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBausch files patent suit against Norwich over generic Xifaxan\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-21 06:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4117798-bausch-files-patent-suit-against-norwich-over-generic-xifaxan><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bausch Health (NYSE:BHC) said it has filed a patent infringement suit against Norwich Pharmaceuticals in response to Norwich's filing of an application with the FDA to put out a generic version of ...</p>\n\n<a href=\"https://seekingalpha.com/news/4117798-bausch-files-patent-suit-against-norwich-over-generic-xifaxan\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://seekingalpha.com/news/4117798-bausch-files-patent-suit-against-norwich-over-generic-xifaxan","article_id":"2445727648","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/687472050/image_687472050.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2445727648","pubTimestamp":1718921475,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Bausch Health  said it has filed a patent infringement suit against Norwich Pharmaceuticals in response to Norwich's filing of an application with the FDA to put out a generic version of Bausch’s Xifaxan 550 mg tablets. Bausch noted that a US District Court in 2022 ruled against Norwich’s first application to market a generic version of the drug. The ruling was later confirmed on appeal. Bausch added it has since received additional patents for the product and intends to “vigorously defend” its intellectual property, according to a statement. Xifaxin 550 mg tablets are approved by the FDA for the reduction in risk of overt hepatic encephalopathy recurrence and the treatment of irritable bowel syndrome with diarrhea, or IBS-D, in adults. Bausch said in mid-May that it had been notified that Norwich had applied to market a generic version of Xifaxin 550 mg for IBS-D. Bausch added that it had 45 days from receipt of the notice to file a patent infringement suit against Norwich, which woul","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BHC":"Bausch Health Companies Inc"},"translate_title":"Bausch就仿制药Xifaxan对Norwich提起专利诉讼","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BHC":1},"content_text":"Bausch Health (NYSE:BHC) said it has filed a patent infringement suit against Norwich Pharmaceuticals in response to Norwich's filing of an application with the FDA to put out a generic version of Bausch’s Xifaxan 550 mg tablets. Bausch noted that a US District Court in 2022 ruled against Norwich’s first application to market a generic version of the drug. The ruling was later confirmed on appeal. Bausch added it has since received additional patents for the product and intends to “vigorously defend” its intellectual property, according to a statement. Xifaxin 550 mg tablets are approved by the FDA for the reduction in risk of overt hepatic encephalopathy recurrence and the treatment of irritable bowel syndrome with diarrhea, or IBS-D, in adults. Bausch said in mid-May that it had been notified that Norwich had applied to market a generic version of Xifaxin 550 mg for IBS-D. Bausch added that it had 45 days from receipt of the notice to file a patent infringement suit against Norwich, which would preclude the FDA from approving Norwich’s application for up to 30 months unless a district court ruled in Norwich’s favor first.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2445727648"}